Whereas anti-TNF strategies have so far been considered standard, a recent comparative monotherapy Phase IV trial in RA patients showed that tocilizumab was more effective than adalimumab in reducing RA-related symptoms.1 This evidence concerns the gene TNF and rheumatoid arthritis.